Open-label safety of Copaxone and neurologic course in MS
Relapsing-Remitting Multiple Sclerosis
Enrolment: 208 · Results not recorded
Loading the evidence…
Drug · Contains components of myelin basic protein and may act as a decoy for the immune response
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Relapsing-Remitting Multiple Sclerosis
Enrolment: 208 · Results not recorded
Multiple Sclerosis
Enrolment: 481 · Results not recorded
Optic Neuritis
Enrolment: 44 · Results not recorded
Relapsing Remitting Multiple Sclerosis
Enrolment: 1008 · Results not recorded
Relapsing Remitting Multiple Sclerosis
Enrolment: 175 · Results not recorded
Crohns Disease
Enrolment: 50 · Results not recorded
Rett Syndrome
Enrolment: 10 · Results not recorded
Amyotrophic Lateral Sclerosis
Enrolment: 366 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Experimental spinal cord injury in rats, with sham-operated and injured untreated control groups; the specific injury method is not stated in the abstract
High-dose glatiramer acetate significantly worsened BBB functional recovery at 12 weeks compared with injury control and low-dose groups, accompanied by increased spinal cavity volume and reduced ventral horn motor neurons. Low-dose treatment did not differ significantly from injury control. High d…
Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.